Trial Profile

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity and Overweight With or Without Type 2 Diabetes Mellitus

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD-6234 (Primary) ; AZD-9550 (Primary) ; Cyclizine hydrochloride; Dapagliflozin; Glucagon; Insulin degludec; Metformin; Ondansetron
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions; Pharmacokinetics
Acronyms CONTEMPO
Sponsors AstraZeneca

19 Nov 2025 Protocol amended to include 2 new arms (Experimental: Part E: AZD9550 and AZD6234 and Experimental: Part E: Placebo) , it has been changed from 8 to 10.
10 Oct 2025 Planned End Date changed from 1 Oct 2026 to 24 Jul 2026.
10 Oct 2025 Planned primary completion date changed from 1 Oct 2026 to 24 Jul 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com